cartitude-5: vrd cilta-cel or rd in newly diagnosed multiple myeloma
Published 2 years ago • 401 plays • Length 2:25Download video MP4
Download video MP3
Similar videos
-
5:05
patient-reported outcomes in cartitude-4: cilta-cel vs soc in r/r multiple myeloma
-
2:17
cilta-cel: a paradigm shift in the treatment of multiple myeloma
-
3:54
cilta-cel as a potential new soc for r/r multiple myeloma: insights from the cartitude-4 trial
-
3:15
cartitude update: patient expectations and experiences of cilta-cel in r/r myeloma
-
4:04
the future of myeloma treatment and the possibility of cure
-
5:19
cramer: this biotech stock could be worth over $100 billion on an fda approval
-
4:38
princess charlotte's emotional moment for mom catherine after her surgery at the hospital
-
1:21
an update on cartitude-2: cilta-cel in patients with multiple myeloma in second line
-
1:47
cilta-cel in earlier lines of therapy for r/r multiple myeloma
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
0:59
phase i study of cart-ddbcma in r/r multiple myeloma
-
2:16
moving car-t therapy into the frontline setting in myeloma: insights into cartitude-5 & cartitude-6
-
2:32
final results of cartitude-1: cilta-cel in heavily pretreated patients with r/r multiple myeloma
-
2:09
cartitude-1: cilta-cel improves hrqol for patients with myeloma
-
2:33
latest results from the cartitude-2 trial of cilta-cel in progressive multiple myeloma
-
5:44
cilta-cel in r/r myeloma: preliminary results from cartitude-1
-
1:03
insights into the cartitude-6 trial: rationale and design
-
2:31
cilta-cel achieves deep and durable responses for r/r multiple myeloma
-
0:48
selecting patients with multiple myeloma for car-t therapy
-
5:15
promising clinical trials for multiple myeloma: karmma, cartitude and evolve
-
3:37
updated data from cartitude-1 and cartitude-2 studies testing cilta-cel in r/r multiple myeloma